Literature DB >> 369677

Eastern Cooperative Oncology Group experience with the rappaport classification of non-Hodgkin's lymphomas.

E Z Ezdinli, W Costello, L P Wasser, R E Lenhard, C W Berard, R Hartsock, J M Bennett, P P Carbone.   

Abstract

Eastern Cooperative Oncology Group experience in the clinical application of the Rappaport Classification on Non-Hodgkin's lymphomas (NHL) is reviewed in 670 cases studied since 1972. The diagnoses of institutional pathologists were reviewed by the Pathology Panel and Repository Center for Lymphoma Clinical Studies. Diagnostic agreement in regard to histologic pattern (nodular versus diffuse) was excellent (90%) but was less favorable when concurrence as to both pattern and cell type was assessed (82% in NLDP and 60% or less in other subtypes). Disagreement in regard to NHL diagnosis is related to the complexity of present nomenclature and to the lack of support of pathology activities within cooperative groups. It is suggested that patients entered into group NHL studies be randomized into favorable and unfavorable groups, primarily on the basis of histological pattern.

Entities:  

Mesh:

Year:  1979        PMID: 369677     DOI: 10.1002/1097-0142(197902)43:2<544::aid-cncr2820430221>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Prognostic value of cytophotometric analysis of DNA in lymph node aspirates from patients with non-Hodgkin's lymphoma.

Authors:  J Vucković; M Dubravcić; J M Matthews; S N Wickramasinghe; M Dominis; B Jaksić
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

2.  Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.

Authors:  Ann S LaCasce; Michelle E Kho; Jonathan W Friedberg; Joyce C Niland; Gregory A Abel; Maria Alma Rodriguez; Myron S Czuczman; Michael M Millenson; Andrew D Zelenetz; Jane C Weeks
Journal:  J Clin Oncol       Date:  2008-09-02       Impact factor: 44.544

3.  Monoclonal antibody phenotyping of B-cell non-Hodgkin's lymphomas. The Southeastern Cancer Study Group experience.

Authors:  M J Borowitz; A Bousvaros; R K Brynes; J B Cousar; J D Crissman; C C Whitcomb; B J Kerns; G E Byrne
Journal:  Am J Pathol       Date:  1985-12       Impact factor: 4.307

4.  Beyond "bad news": the diagnosis, prognosis and classification of lymphomas and lymphoma patients in the age of biomedicine (1945-1995).

Authors:  Peter Keating; Alberto Cambrosio
Journal:  Med Hist       Date:  2003-07       Impact factor: 1.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.